Status:
TERMINATED
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes
Lead Sponsor:
Azienda Ospedaliero-Universitaria di Parma
Conditions:
Acute Coronary Syndromes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndromes, and is therefore one of the most frequently prescribed drugs ...
Detailed Description
Antiplatelet therapy is the cornerstone of medical treatment of patients experiencing an acute coronary syndrome (ACS). As a synergistic antiplatelet effect can be obtained by simultaneously inhibitin...
Eligibility Criteria
Inclusion
- Diagnosis of ACS (STE-ACS or NSTE-ACS) during the index hospitalisation
- Age \>18 years
- Ability to sign the informed consent form
- Ability to attend scheduled visits
Exclusion
- Cognitive or other causes of an inability to provide informed consent or follow study procedures
- Any contraindication to the use of ADP P2Y12 inhibitors
- Life expectancy \<1 year
- Thrombolytic therapy within the previous 24 hours
- Known ABCB1, CYP2C19 \*2 orCYP2C19 \*17 genotype
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
889 Patients enrolled
Trial Details
Trial ID
NCT03347435
Start Date
June 1 2013
End Date
March 1 2015
Last Update
November 20 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Ramazzini
Carpi, Modena, Italy, 41012
2
Ospedale di Vaio
Fidenza, Parma, Italy, 43036
3
Azienda Ospedaliero Universitaria di Parma
Parma, Italy, 43123
4
Ospedale Guglielmo da Saliceto
Piacenza, Italy, 29121